BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Frequently asked questions
What sector does BioAge Labs, Inc (BIOA) operate in?
BioAge Labs, Inc belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is BioAge Labs, Inc (BIOA) current stock price?
As of the latest data, BioAge Labs, Inc stock price is $10.60, with a previous close of $10.43. BioAge Labs, Inc gained $0.17 in the last trading session, representing a 1.63% increase.
What is BioAge Labs, Inc (BIOA) current market capitalization?
BioAge Labs, Inc market cap is approximately 486.51 million.
What is BioAge Labs, Inc (BIOA) Earnings Per Share (EPS)?
The trailing EPS is -$2.49, and the forward EPS is -$2.41.
What is BioAge Labs, Inc (BIOA) EBITDA?
BioAge Labs, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -29.33 million.
Does BioAge Labs, Inc (BIOA) pay dividends?
No. BioAge Labs, Inc does not pay a dividend.
How did BioAge Labs, Inc (BIOA) perform in its most recent earnings report?
In the last report (June 30, 2026), BioAge Labs, Inc posted an EPS surprise of 10.77% and a revenue surprise of 63.65%.
What is BioAge Labs, Inc (BIOA) beta (volatility) score?
BioAge Labs, Inc has a beta of 0.528, indicating lower volatility than the overall market.
